Follow RSS for latest reports on this topicErtugliflozin - Market Research and Reports

Ertugliflozin a sodium glucose cotransporter-2 (SGLT2) inhibitor, under development by Pfizer and Merck & Co. for the treatment of type 2 diabetes (T2D).  By blocking SGLT2 in the proximal tubules of the kidney, ertugliflozin removes excess glucose in the blood by preventing the reabsorption of filtered glucose.

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data
{STICKYFOOTERMOBILE}